Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT1062230034
JPRN-jRCT1062230034
Recruiting
未知

A single-center open-label crossover study of the clinical utility and safety of the BV-UFC system of the DCS-200Si dialysis monitor

Hamada Shintaro0 sites20 target enrollmentJuly 4, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPatients undergoing hemodialysishemodialysisD006435

Overview

Phase
未知
Intervention
Not specified
Conditions
Patients undergoing hemodialysis
Sponsor
Hamada Shintaro
Enrollment
20
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 4, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hamada Shintaro

Eligibility Criteria

Inclusion Criteria

  • •(1\) Patients who give written consent to participate in this study of their own free will.
  • •(2\)Hemodialysis patients who are outpatients or inpatients undergoing hemodialysis (regardless of the underlying disease)
  • •(3\)Patients who are between 20 and 90 years old (regardless of gender) at the time of consent
  • •(4\)Patients who can be get a blood flow rate of 200 mL/min or more by vascular access
  • •(5\)Patients who have been receiving hemodialysis for at least 3 months at the time of participation in this study

Exclusion Criteria

  • •Of those who meet the above selection criteria, those who meet any of the following criteria shall not be eligible for enrollment.
  • •(1\) Patients participating in other clinical research or clinical trials
  • •(2\)Those who are pregnant
  • •(3\)Patients who have vascular access recirculation
  • •(4\) Patients who are deemed by the investigator to be inappropriate to participate in the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
ivolumab after selective internal radiation therapy using SIR-Spheres to treat patients with primary liver cancer: a safety and efficacy study
EUCTR2017-000232-34-ESClínica Universidad de Navarra/Universidad de Navarra42
Unknown
Phase 1
DS-8500a atorvastatin DDI studyHealthy volunteers
JPRN-jRCT2080222826DAIICHISANKYO Co.,Ltd.28
Completed
Phase 4
A multicenter, Single arm, Open label study of The Repeated Administration Of Qutenza For The Treatment Of Peripheral Neuropathic Pain.pain that is caused by damage to the peripheral nervesPeripheral Neuropathic Pain10034606
NL-OMON34497Astellas Pharma B.V.12
Recruiting
Phase 3
An open-label, single-arm, multicenter study of intracerebral administration of adeno-associated viral vectors serotype rh.10 carrying the human N-sulfoglycosamine sulfohydrolase (SGSH) cDNA for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA)MPS IIISanfilippo syndrome1002742410057167
NL-OMON52445ysogene SA10
Active, not recruiting
Phase 1
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain - STRIDEPeripheral Neuropathic Pain in Postherpetic Neuralgia (PHN), Painful HIV-Associated Neuropathy (HIV-AN), Peripheral Neuropathic Injury (PNI), Idiopathic Small Nerve Neuropathy (ISNN) or other Peripheral Neuropathic Pain (PNP).MedDRA version: 12.1Level: LLTClassification code 10054095Term: Neuropathic pain
EUCTR2009-016457-18-SKAstellas Pharma Europe Ltd300